Mutant er.alpha. and test systems for transactivation
CA 2393045 A1 · Owner: Satoh, Hideo · Inventors: Saito, Koichi; Ohe, Norihisa; Satoh, Hideo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides in general an artificial cell an isolated , mutant ER.alpha. an isolated polynucleotide encoding the mutant ER.alpha. a method for quantitatively analyzing an activity for transactivation of a reporter gene by a test ER.alpha. a method for screening a mutant ligand dependent transcriptional factor, a method for evaluating an activity for transactivation of a reporter gene by a test ER.alpha. a method for screening a compound useful for treating a disorder of a mutant ER.alpha. a pharmaceutical agent useful for treating an estrogenic disorder of a mutant ER.alpha. use of the mutant ER.alpha. a method for diagnosing a genotype of a polynucleotide …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 1, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 1, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 1, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.